Biotech & AI drug discoveryNature Medicine

EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial

Nature Medicine published a phase 1 trial of an EGFR-targeted antibody-toxin conjugate in recurrent glioma. The feed provides no further details; results and conclusions are as reported in the original article.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-16T00:00:00+00:00

Published here2026-10-21T05:07:27+00:00

Original source

Nature Medicine

Media report · consult original reporting

Read the original ↗https://www.nature.com/articles/s41591-026-04715-w

Original headline

EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.